Diagnostic accuracy of serum human epididymis protein 4 in ovarian cancer patients with different ethnic groups and menopausal status: a meta-analysis and systematic evaluation

Sun, Rui; Liu, Lin; Feng, Zhengli; Ni, Ao; Guo, Qing

doi:10.5603/gp.a2022.0128

Cited by 1 publication

(2 citation statements)

References 30 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, HE4 is elevated at an earlier stage in the progression of the disease [84,89]. Nevertheless, the concentration of HE4 is substantially influenced by age [86].…”

Section: Human Epididymis Protein 4 (He4)mentioning

confidence: 99%

“…Notably, HE4 is up regulated in OC, and its elevated levels have been observed in serous, endometrioid, and clear-cell ovarian tumors. Furthermore, HE4 has shown increased expression in patients with mucinous ovarian tumors, which distinguishes it from CA125 [84][85][86][87][88]. In contrast to CA125, HE4 offers several advantages as a biomarker.…”

Section: Human Epididymis Protein 4 (He4)mentioning

confidence: 99%

See 1 more Smart Citation

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements in the treatment, most OC patients still die from their disease due to late-stage diagnosis, the lack of effective diagnostic methods, and relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability to selectively bind to target molecules, including cancer-related proteins and receptors, has revolutionized drug discovery and biomarker identification. Aptamers offer unique insights into the molecular pathways involved in cancer development and progression. Moreover, they show immense potential as drug delivery systems, enabling targeted delivery of therapeutic agents to cancer cells while minimizing off-target effects and reducing systemic toxicity. In the context of OC, the integration of aptamers with non-coding RNAs (ncRNAs) presents an opportunity for precise and efficient gene targeting. Additionally, the conjugation of aptamers with nanoparticles allows for accurate and targeted delivery of ncRNAs to specific cells, tissues, or organs. In this review, we will summarize the potential use and challenges associated with the use of aptamers alone or aptamer–ncRNA conjugates, nanoparticles, and multivalent aptamer-based therapeutics for the treatment of OC.

show abstract

“…Additionally, HE4 is elevated at an earlier stage in the progression of the disease [84,89]. Nevertheless, the concentration of HE4 is substantially influenced by age [86].…”

Section: Human Epididymis Protein 4 (He4)mentioning

confidence: 99%

Section: Human Epididymis Protein 4 (He4)mentioning

confidence: 99%

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Diagnostic accuracy of serum human epididymis protein 4 in ovarian cancer patients with different ethnic groups and menopausal status: a meta-analysis and systematic evaluation

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Ginekologia Polska" are listed in PubMed.

Cited by 1 publication

References 30 publications

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Contact Info

Product

Resources

About